Kamu erişimi zorunlu olan makaleler - Sumanta PalDaha fazla bilgi edinin
Hiçbir yerde sunulmuyor: 26
Genomic characterization of renal cell carcinoma with sarcomatoid dedifferentiation pinpoints recurrent genomic alterations
GG Malouf, SM Ali, K Wang, S Balasubramanian, JS Ross, VA Miller, ...
European urology 70 (2), 348-357, 2016
Zorunlu olanlar: US National Institutes of Health
Randomized, double-blind phase III study of pazopanib versus placebo in patients with metastatic renal cell carcinoma who have no evidence of disease following metastasectomy …
LJ Appleman, M Puligandla, SK Pal, W Harris, N Agarwal, BA Costello, ...
Journal of Clinical Oncology 37 (15_suppl), 4502-4502, 2019
Zorunlu olanlar: US National Institutes of Health
Understanding caregiver quality of life in caregivers of hospitalized older adults with cancer
T Hsu, N Nathwani, M Loscalzo, V Chung, J Chao, C Karanes, ...
Journal of the American Geriatrics Society 67 (5), 978-986, 2019
Zorunlu olanlar: US National Institutes of Health, Canadian Institutes of Health Research
Complications after metastasectomy for renal cell carcinoma—A population-based assessment
CP Meyer, M Sun, JA Karam, JJ Leow, G de Velasco, SK Pal, SL Chang, ...
European urology 72 (2), 171-174, 2017
Zorunlu olanlar: US National Institutes of Health
Targeting angiopoietin-2 signaling in cancer therapy
Z Eroglu, CA Stein, SK Pal
Expert opinion on investigational drugs 22 (7), 813-825, 2013
Zorunlu olanlar: US National Institutes of Health
Optimizing systemic therapy for bladder cancer
SK Pal, MI Milowsky, ER Plimack
Journal of the National Comprehensive Cancer Network 11 (7), 793-804, 2013
Zorunlu olanlar: US National Institutes of Health
Targeted therapies for renal cell carcinoma: understanding their impact on survival
SK Pal, RA Figlin
Targeted oncology 5, 131-138, 2010
Zorunlu olanlar: US National Institutes of Health
Emotional problem‐related distress screening and its prevalence by cancer type: Assessment by patients' characteristics and level of assistance requested
CD Bergerot, M Razavi, KL Clark, EJ Philip, SK Pal, M Loscalzo, W Dale
Psycho‐Oncology 30 (8), 1332-1338, 2021
Zorunlu olanlar: US National Institutes of Health
Management of non-small-cell lung cancer in the older adult
A VanderWalde, SK Pal, KL Reckamp
Maturitas 68 (4), 311-321, 2011
Zorunlu olanlar: US National Institutes of Health
Oncologists' Recommendations for Adjuvant Therapy in Hormone Receptor—Positive Breast Cancer Patients of Varying Age and Health Status
A Naeim, FL Wong, SK Pal, A Hurria
Clinical breast cancer 10 (2), 136-143, 2010
Zorunlu olanlar: US National Institutes of Health
Local treatment of the primary tumor for patients with metastatic cancer (PRIME-TX): a meta-analysis
JM Ryckman, TV Thomas, M Wang, X Wu, S Siva, DE Spratt, B Slotman, ...
International Journal of Radiation Oncology* Biology* Physics 114 (5), 919-935, 2022
Zorunlu olanlar: US National Institutes of Health
Comparative effectiveness of immune checkpoint inhibitors in patients with platinum refractory advanced urothelial carcinoma
U Swami, B Haaland, A Kessel, R Nussenzveig, BL Maughan, J Esther, ...
The Journal of Urology 205 (3), 709-717, 2021
Zorunlu olanlar: US National Institutes of Health
Pazopanib: carving a niche in a crowded therapeutic landscape
SK Pal, RA Figlin
Nature Reviews Clinical Oncology 7 (7), 362-363, 2010
Zorunlu olanlar: US National Institutes of Health
Physical activity and risk of bladder cancer among postmenopausal women
Y Li, MS Hendryx, P Xun, K He, AH Shadyab, DS Lane, R Nassir, ...
International journal of cancer 147 (10), 2717-2724, 2020
Zorunlu olanlar: US National Institutes of Health
Patterns of treatment in metastatic renal cell carcinoma for older versus younger patients
AW Hahn, J Esther, B Haaland, U Swami, N Dizman, N Rathi, ...
Journal of Geriatric Oncology 11 (4), 724-726, 2020
Zorunlu olanlar: US National Institutes of Health
Real-world effectiveness of everolimus subsequent to different first targeted therapies for the treatment of metastatic renal cell carcinoma: synthesis of retrospective chart …
SK Pal, JE Signorovitch, WM Reichmann, N Li, V Koo, Z Liu, JR Perez, ...
Clinical Genitourinary Cancer 14 (2), 160-167. e3, 2016
Zorunlu olanlar: US National Institutes of Health
HSD3B1—A Predictive Biomarker in Advanced Prostate Cancer
AW Hahn, SK Pal, N Agarwal
JAMA oncology 4 (4), 562-563, 2018
Zorunlu olanlar: US Department of Defense, US National Institutes of Health, Howard Hughes …
Seasonal incidence of pulse aphid (Aphis craccivora Koch.) and its natural enemies on field pea (Pisum sativum L.) in relation to some abiotic factors in Alluvial Zone of West …
S Pal, S Samanta, A Banerjee
Legume Research 46 (12), 1680-1685, 2023
Zorunlu olanlar: Indian Council of Agricultural Research
Blood-based gene expression signature associated with metastatic castrate-resistant prostate cancer patient response to abiraterone plus prednisone or enzalutamide
NB Haas, MJ LaRiviere, TH Buckingham, Y Cherkas, K Calara-Nielsen, ...
Prostate Cancer and Prostatic Diseases 24 (2), 448-456, 2021
Zorunlu olanlar: US National Institutes of Health
Emerging Agents in Renal Cell Carcinoma
SK Pal, DY Josephson, P Twardowski, DI Quinn
Kidney Cancer: Principles and Practice, 285-301, 2011
Zorunlu olanlar: US National Institutes of Health
Yayıncılık ve maddi kaynak bilgileri otomatik olarak bir bilgisayar programı tarafından belirlenmektedir